viewCannPal Animal Therapeutics Ltd

CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market

This is a niche space that is growing fast and CannPal already has an advantage through its research and product development programs which are well underway.

a dog and a man
CannPal recently received key ethics approvals to progress its lead therapeutic products

CannPal Animal Therapeutics Ltd (ASX:CP1) is well placed to benefit from the rapidly growing cannabinoids-based animal health market.

Focusing on animal well-being, particularly companion pets (e.g., cats and dogs) could be lucrative for the company.

According to the American Pet Product Association, annual pet industry expenditure in the U.S. has grown in each of the past 18 years, with Americans estimated to have spent $18.3 billion on veterinary care and $15.5 billion on supplies and over-the-counter medicines in 2018.

READ: CannPal Animal Therapeutics receives approvals for two clinical studies

The company recently received two key ethics approvals to progress the research and development of its lead therapeutic products, CPAT-01 and DermaCann.

CPAT-01 is a pain and inflammatory control being developed for dogs and DermaCann is a nutraceutical product in development to promote canine skin health.

CannPal hopes to complete recruitment for both studies by mid CY2019.

Elixinol Global gaining traction in the pet space

Many players in the industrial hemp and cannabidiol (CBD) based dietary supplement market are seeing a growing market for their products catering to the pet industry.

This includes Elixinol Global Ltd (ASX:EXL), manufacturer of Edibites, a CBD pet treat specifically formulated for dogs.

Elixinol recently witnessed an increase in private label production which now accounts for around 40% of its U.S. revenue of $32.5 million in 2018, with one large customer in the pet space driving most of the private label growth.

Cannabinoids-based animal health is a niche space that is growing fast and CannPal already has an advantage through its research and product development programs which are well underway.

Quick facts: CannPal Animal Therapeutics Ltd

Price: 0.093 AUD

Market: ASX
Market Cap: $8.66 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...



CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear,...

on 06/24/2018

2 min read